RGEN Repligen Corp

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.

• RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investors.
• Craig-Hallum’s 22nd Annual Institutional Investor Conference, being held in Minneapolis on May 28. Jason K. Garland, Chief Financial Officer will participate in a series of one-on-one meetings with investors.

A live webcast of the RBC conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen CorporationRepligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact: Jacob JohnsonVP, Investor Relations(781) 419-0204investors@repligen.com